A recent case report about a man who received an mRNA-based COVID-19 vaccine suggests that taking the vaccine “may trigger immune-mediated hepatitis,” researchers wrote.
The case report does not indicate how common such a case would be, although researchers said that such a scenario is recognized as a “rare adverse event not identified in early trials.”
Researchers said they found that highly-activated T cells “accumulate and are evenly distributed in the different areas” of the man’s liver after he took the COVID-19 vaccine and developed acute hepatitis. T cells are a type of white blood cell that comprise a key part of the immune system. These cells focus on fighting new infections.
The patient experienced nausea and fatigue about 10 days after his first dose of the vaccine, and was subsequently found to have acute hepatitis. The hepatitis resolved on its own after about three days. He had a second dose of the vaccine 41 days after his first dose. Symptoms of nausea and fatigue returned 20 days later—he was given an oral steroid medication and initially improved. He relapsed 39 days later, after which he was successfully treated with systemic immunosuppressive therapy that also included steroids. The man’s liver function tests “subsequently normalized within 8 weeks.”
Researchers said the man’s immune response to the COVID-19 vaccine may have contributed to his liver inflammation. The COVID-19 vaccine from Pfizer “may trigger immune-mediated hepatitis by mechanisms linked to vaccine-induced cellular immunity,” they said in the case report.
Within the T cells that were found in the liver, the scientists observed “an enrichment of T cells that are reactive to SARS-CoV-2, suggesting that these vaccine-induced cells can contribute to the liver inflammation in this context.”
Specifically, the type of T cell called CD8 T cells “represented the most abundant immune cell subset” found in the liver. “Our analysis highlights that activated cytotoxic CD8 T cells including vaccine-induced spike-specific CD8 T cells could contribute to disease pathogenesis,” researchers wrote.
“Based on their strong enrichment ... we speculated that CD8 T cells could be drivers of the hepatic inflammation.”
The authors called the case one that appears to be autoimmune hepatitis, but is not.
“Autoimmune-hepatitis-like disease after vaccination against SARS-CoV-2 is now recognized as a rare adverse event not identified in early trials,” they wrote. “The widespread use of the vaccine with administration of hundreds of million doses worldwide raises also questions of causality vs. coincidence.”
The authors wrote it is important to differentiate autoimmune hepatitis from hepatitis triggered by immune responses after COVID-19 vaccination; the former requires lifelong immunosuppressive therapy in many patients, while the latter is possibly transient, they noted.
